RESUMO
Parkinson's disease (PD) is a neurodegenerative disease that is primarily characterized by degeneration of dopaminergic (DA) neurons in the substantia nigra (SN) and a loss of their fibre projections in the striatum. We utilized the neonatal porcine choroid plexus (CP), an organ that secretes cerebrospinal fluid containing various types of neurotrophic and neuroprotective factors, to ameliorate the Parkinsonian symptoms in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-treated rhesus monkeys without requiring immunosuppression. We demonstrate that transplanted encapsulated CP clusters (eCPs) significantly improved neurological functions in MPTP-treated monkeys during the course of six months after transplantation (p < 0.001) when compared with monkeys implanted with empty capsules or subjected to sham surgery. The improvement in neurological scores was accompanied by a corresponding improvement in apomorphine-induced circling behaviour (p < 0.001) as well as increased tyrosine hydroxylase (TH) staining in the striatum. Our results suggest that eCPs are a promising cell therapeutic agent to treat Parkinson's disease.
Assuntos
Transplante de Células/métodos , Plexo Corióideo/citologia , Intoxicação por MPTP/cirurgia , Doença de Parkinson Secundária/cirurgia , Animais , Animais Recém-Nascidos , Apomorfina , Agonistas de Dopamina , Imuno-Histoquímica , Intoxicação por MPTP/patologia , Macaca mulatta , Masculino , Movimento/fisiologia , Neostriado/metabolismo , Rede Nervosa/citologia , Rede Nervosa/fisiologia , Exame Neurológico , Doença de Parkinson Secundária/induzido quimicamente , Doença de Parkinson Secundária/patologia , Postura/fisiologia , Recuperação de Função Fisiológica , Rotação , Suínos , Tirosina 3-Mono-Oxigenase/metabolismoRESUMO
Cochlear implants provide partial restoration of hearing for profoundly deaf patients by electrically stimulating spiral ganglion neurons (SGNs); however, these neurons gradually degenerate following the onset of deafness. Although the exogenous application of neurotrophins (NTs) can prevent SGN loss, current techniques to administer NTs for long periods of time have limited clinical applicability. We have used encapsulated choroid plexus cells (NTCells; Living Cell Technologies, Auckland, New Zealand) to provide NTs in a clinically viable manner that can be combined with a cochlear implant. Neonatal cats were deafened and unilaterally implanted with NTCells and a cochlear implant. Animals received chronic electrical stimulation (ES) alone, NTs alone, or combined NTs and ES (ES + NT) for a period of as much as 8 months. The opposite ear served as a deafened unimplanted control. Chronic ES alone did not result in increased survival of SGNs or their peripheral processes. NT treatment alone resulted in greater SGN survival restricted to the upper basal cochlear region and an increased density of SGN peripheral processes. Importantly, chronic ES in combination with NTs provided significant SGN survival throughout a wider extent of the cochlea, in addition to an increased peripheral process density. Re-sprouting peripheral processes were observed in the scala media and scala tympani, raising the possibility of direct contact between peripheral processes and a cochlear implant electrode array. We conclude that cell-based therapy is clinically viable and effective in promoting SGN survival for extended durations of cochlear implant use. These findings have important implications for the safe delivery of therapeutic drugs to the cochlea.
Assuntos
Terapia Baseada em Transplante de Células e Tecidos/métodos , Implante Coclear/métodos , Surdez/tratamento farmacológico , Surdez/cirurgia , Próteses Neurais , Animais , Animais Recém-Nascidos , Gatos , Sobrevivência Celular/efeitos dos fármacos , Estimulação Elétrica/métodos , Potenciais Evocados Auditivos do Tronco Encefálico , Feminino , Masculino , Fatores de Crescimento Neural/uso terapêutico , Proteínas de NeurofilamentosRESUMO
AIM: To restore motor function and dopaminergic activity in the nigrostriatum of rats with unilateral 6-hydroxy-dopamine lesions using implants of encapsulated porcine choroid plexus cells. MATERIALS & METHODS: Neonatal porcine choroid plexus cells were prepared and maintained in culture, then encapsulated within alginate-polyornithine capsules (600-660 µm). Rats were unilaterally injected with 6-hydroxy-dopamine into the striatum. Those with lesions verified after 2 and 4 weeks were selected for experiments. Rats were implanted adjacent to the lesion with ten capsules 2-4 days later with (treated, n = 12) or without (control, n = 10) choroid plexus cells. RESULTS: The choroid plexus cells were shown to produce a wide range of neurorestorative proteins. The treated group had a 60% improvement in motor behavior compared with the control group (p < 0.01). The treated group also had a significant improvement in nigrostriatal dopaminergic activity (31%, p < 0.02). CONCLUSION: Capsules containing porcine choroid plexus cells release therapeutic molecules that stimulate regeneration of the lesioned nigrostriatum in rats.
Assuntos
Atividade Motora/fisiologia , Neostriado/patologia , Neostriado/fisiopatologia , Recuperação de Função Fisiológica/fisiologia , Animais , Comportamento Animal , Transplante de Células , Plexo Corióideo/citologia , Imuno-Histoquímica , Implantes Experimentais , Neostriado/metabolismo , Oxidopamina , Ratos , Sus scrofa , Tirosina 3-Mono-Oxigenase/metabolismoRESUMO
Exogenous neurotrophin delivery to the deaf cochlea can prevent deafness-induced auditory neuron degeneration, however, we have previously reported that these survival effects are rapidly lost if the treatment stops. In addition, there are concerns that current experimental techniques are not safe enough to be used clinically. Therefore, for such treatments to be clinically transferable, methods of neurotrophin treatment that are safe, biocompatible and can support long-term auditory neuron survival are necessary. Cell transplantation and gene transfer, combined with encapsulation technologies, have the potential to address these issues. This study investigated the survival-promoting effects of encapsulated BDNF over-expressing Schwann cells on auditory neurons in the deaf guinea pig. In comparison to control (empty) capsules, there was significantly greater auditory neuron survival following the cell-based BDNF treatment. Concurrent use of a cochlear implant is expected to result in even greater auditory neuron survival, and provide a clinically relevant method to support auditory neuron survival that may lead to improved speech perception and language outcomes for cochlear implant patients.
Assuntos
Fator Neurotrófico Derivado do Encéfalo/farmacologia , Fator Neurotrófico Derivado do Encéfalo/uso terapêutico , Nervo Coclear/efeitos dos fármacos , Nervo Coclear/patologia , Surdez/tratamento farmacológico , Neurônios/patologia , Células de Schwann/transplante , Alginatos/farmacologia , Animais , Cápsulas , Sobrevivência Celular/efeitos dos fármacos , Implante Coclear , Surdez/patologia , Ácido Glucurônico/farmacologia , Cobaias , Ácidos Hexurônicos/farmacologia , Neurônios/efeitos dos fármacos , Ratos , Células de Schwann/efeitos dos fármacos , TransfecçãoRESUMO
The choroid plexus (CP) produces and secretes numerous biologically active neurotrophic factors into the cerebrospinal fluid (CSF). These circulate throughout the brain and spinal cord, maintaining neuronal networks and associated cells. In neurodegenerative disease and in acute brain injury there is local up-regulation of neurotrophin production close to the site of the lesion. Treatment by direct injection of neurotrophins and growth factors close to these lesion sites has repeatedly been demonstrated to improve recovery. It has therefore been proposed that transplanting viable choroid plexus cells close to the lesion might provide a novel means for continuous delivery of these molecules directly to the site of injury. Recent publications describe how transplanted CP, either free or in an immunoprotected encapsulated form, deliver therapeutic molecules to the desired site. This review briefly describes the accumulated evidence that CP cells support neuronal cells in vitro and have therapeutic properties when transplanted to treat acute and chronic brain disease and injury in animal models.